KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

CIFRAN 250 MG TABLETS

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

250 MG

 

GENERIC NAME:

CIPROFLOXACIN

 

MANUFACTURER:

RANBAXY LAB. LTD

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

C

 

INDICATIONS:

Anthrax

Bronchitis, chronic, acute exacerbation

Conjunctivitis, infectious

Diarrhea, infectious

Gonorrhea

Infection, bone

Infection, intra- abdominal

Infection, joint

Infection, lower respiratory tract

Infection, sexually transmitted

Infection, sinus

Infection, skin and skin structure

Infection, upper respiratory tract

Infection, urinary tract

Neutropenia, febrile

Pneumonia

Prostatitis

Pyelonephritis

Typhoid fever

Ulcer, corneal

 

SIDE EFFECTS:

confusion

conjunctival hyperemia

corneal deposits

crystalluria

depression

diaphoresis

diarrhea

diplopia

dizziness

drowsiness

dysesthesia

dysgeusia

dyspepsia

dysphagia

dyspnea

eosinophilia

epistaxis

erythema

erythema nodosum

fever

flushing

hallucinations

headache

hearing loss

hemolytic anemia

hemoptysis

hepatitis

hiccups

hypertension

hypoesthesia

hypotension

increased intracranial pressure

insomnia

interstitial nephritis

irritability

jaundice

laryngeal edema

lethargy

lymphadenopathy

maculopapular rash

mania

migraine

myalgia

nausea/vomiting

nightmares

ocular pain

palpitations

paranoia

paresthesias

peripheral neuropathy

peripheral vasodilation

petechiae

phlebitis

phobia

photosensitivity

polyuria

pruritus

pseudomembranous colitis

psychosis

pulmonary edema

pulmonary embolism

QT prolongation

rash (unspecified)

rhinitis

seizures

sinus tachycardia

skin hyperpigmentation

abdominal pain

acute generalized exanthematous pustulosis (AGEP)

agitation

anaphylactic shock

anaphylactoid reactions

angioedema

anorexia

anxiety

arthralgia

arthropathy

ataxia

atrial flutter

back pain

blurred vision

bone pain

bronchospasm

candidiasis

chills

cholestasis

suicidal ideation

tendon rupture

thrombocytopenia

tinnitus

torsade de pointes

toxic epidermal necrolysis

tremor

urinary retention

urticaria

vaginitis

vertigo

visual impairment

weakness

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

arteriosclerosis

atrial fibrillation

bradycardia

breast-feeding

cerebrovascular disease

children

colitis

dehydration

elderly

GI disease

heart failure

hepatic disease

myasthenia gravis

pregnancy

renal impairment

seizures

syphilis

 

ADULT DOSE:

Anthrax, inhalational (treatment) - Oral, 500 mg (base) every 12 hours for 60 days. Bone and joint infections- Mild or moderate: Oral, 500 mg (base) every twelve hours for at least four to six weeks . Severe or complicated: Oral, 750 mg (base) every twelve hours for at least four to six weeks . Diarrhea, infectious- Mild to severe: Oral, 500 mg (base) every twelve hours for five to seven days . Gonorrhea, endocervical and urethral- Oral, 250 mg (base) as a single dose . Intra-abdominal infections- Oral, 500 mg (base) every twelve hours for seven to fourteen days, in combination with oral metronidazole . Lower respiratory tract infections- Mild to moderate: Oral, 500 mg (base) every twelve hours for seven to fourteen days . Severe or complicated: Oral, 750 mg (base) every twelve hours for seven to fourteen days . [Meningococcal carriers ]- Oral, 750 mg (base) as a single dose . Prostatitis, chronic- Mild or moderate: Oral, 500 mg (base) every twelve hours for twenty-eight days . Sinusitis, mild or moderate or Typhoid fever- Oral, 500 mg (base) every twelve hours for ten days . Skin and soft tissue infections- Mild or moderate: Oral, 500 mg (base) every twelve hours for seven to fourteen days . Severe or complicated: Oral, 750 mg (base) every twelve hours for seven to fourteen days . Urinary tract infections- Acute uncomplicated: Oral, 100 mg (base) every twelve hours for three days . Mild or moderate: Oral, 250 mg (base) every twelve hours for seven to fourteen days . Severe or complicated: Oral, 500 mg (base) every twelve hours for seven to fourteen days . Note: Adults with impaired renal function may require a reduction in dose as follows : Creatinine clearance (mL/min)/(mL/sec) Dose (base) > 50/0.83 See 30-50/0.5-0.83 250-500 mg every 12 hours 5-29/0.08-0.48 250-500 mg every 18 hours Hemodialysis or Peritoneal dialysis 250-500 mg every 24 hours after dialysis patients In patients with severe infection and severe renal function impairment, a unit dose of 750 mg may be administered at the intervals noted above; however, these patients should be monitored carefully and serum concentrations of ciprofloxacin should be measured periodically .

 

MAXIMUM ADULT DOSE:

1.5 grams (base) daily .

 

PEDIATRIC DOSE:

Children up to 18 years of age-Use is not recommended in infants, children, or adolescents since fluoroquinolones cause arthropathy in immature animals . However, ciprofloxacin has been given to pediatric patients, as indicated below, when alternative therapy could not be used. Based on pharmacokinetic studies, dosing for patients with cystic fibrosis should be higher and at more frequent intervals than for patients without cystic fibrosis . Dosing for cystic fibrosis patients also should be decreased as body weight increases . Anthrax, inhalational (treatment) - Oral, 15 mg per kg of body weight per dose (base), not to exceed 500 mg per dose, every 12 hours for 60 days. [Cystic fibrosis, pulmonary exacerbations] - For children 14 to 28 kg of body weight: Oral, 28 to 20 mg (base) per kg of body weight every twelve hours, up to 2 grams per day . For children 28 to 42 kg of body weight: Oral, 20 to 15 mg (base) per kg of body weight every twelve hours, up to 2 grams per day . [For other infections] - Oral, 10 to 15 mg (base) per kg of body weight twice a day, up to 1.5 grams per day . 

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

Anthrax, inhalational (treatment) - Oral, 500 mg (base) every 12 hours for 60 days. Bone and joint infections- Mild or moderate: Oral, 500 mg (base) every twelve hours for at least four to six weeks . Severe or complicated: Oral, 750 mg (base) every twelve hours for at least four to six weeks . Diarrhea, infectious- Mild to severe: Oral, 500 mg (base) every twelve hours for five to seven days . Gonorrhea, endocervical and urethral- Oral, 250 mg (base) as a single dose . Intra-abdominal infections- Oral, 500 mg (base) every twelve hours for seven to fourteen days, in combination with oral metronidazole . Lower respiratory tract infections- Mild to moderate: Oral, 500 mg (base) every twelve hours for seven to fourteen days . Severe or complicated: Oral, 750 mg (base) every twelve hours for seven to fourteen days . [Meningococcal carriers ]- Oral, 750 mg (base) as a single dose . Prostatitis, chronic- Mild or moderate: Oral, 500 mg (base) every twelve hours for twenty-eight days . Sinusitis, mild or moderate or Typhoid fever- Oral, 500 mg (base) every twelve hours for ten days . Skin and soft tissue infections- Mild or moderate: Oral, 500 mg (base) every twelve hours for seven to fourteen days . Severe or complicated: Oral, 750 mg (base) every twelve hours for seven to fourteen days . Urinary tract infections- Acute uncomplicated: Oral, 100 mg (base) every twelve hours for three days . Mild or moderate: Oral, 250 mg (base) every twelve hours for seven to fourteen days . Severe or complicated: Oral, 500 mg (base) every twelve hours for seven to fourteen days . Note: Adults with impaired renal function may require a reduction in dose as follows : Creatinine clearance (mL/min)/(mL/sec) Dose (base) > 50/0.83 See 30-50/0.5-0.83 250-500 mg every 12 hours 5-29/0.08-0.48 250-500 mg every 18 hours Hemodialysis or Peritoneal dialysis 250-500 mg every 24 hours after dialysis patients In patients with severe infection and severe renal function impairment, a unit dose of 750 mg may be administered at the intervals noted above; however, these patients should be monitored carefully and serum concentrations of ciprofloxacin should be measured periodically .

 

 

PREVIOUS

  

NEXT